Connection
Michele Fox to Bone Marrow Transplantation
This is a "connection" page, showing publications Michele Fox has written about Bone Marrow Transplantation.
|
|
Connection Strength |
|
|
|
|
|
1.921 |
|
|
|
-
Rosenbaum ER, Pandey S, Harville TO, Drobena GA, Cottler-Fox M. Flow Cytometric Panel-Reactive Antibody Results and the Ability to Find Transfusion-Compatible Platelets after Antibody-Desensitization for Allogeneic Bone Marrow Transplant. Ann Clin Lab Sci. 2016 Dec; 46(6):662-665.
Score: 0.278
-
Fassas AB, Buddharaju LN, Rapoport A, Cottler-Fox M, Drachenberg C, Meisenberg B, Tricot G. Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation. Leuk Lymphoma. 2001 Aug; 42(4):801-4.
Score: 0.192
-
Fassas AB, Rapoport AP, Cottler-Fox M, Chen T, Tricot G. Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation. Br J Haematol. 2000 Nov; 111(2):662-7.
Score: 0.183
-
Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, Rapoport AP, Cottler-Fox M, Tricot G, Ruehle K, Meisenberg B. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion. 2003 Jan; 43(1):78-84.
Score: 0.106
-
Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9.
Score: 0.100
-
Przepiorka D, Phillips GL, Ratanatharathorn V, Cottler-Fox M, Sehn LH, Antin JH, LeBherz D, Awwad M, Hope J, McClain JB. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998 Dec 01; 92(11):4066-71.
Score: 0.080
-
Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 1998 Mar; 21(6):543-51.
Score: 0.076
-
Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996 Oct 15; 88(8):3223-9.
Score: 0.069
-
Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 1995 Jun 01; 85(11):3048-57.
Score: 0.063
-
Dunbar CE, Bodine DM, Sorrentino B, Donahue R, McDonagh K, Cottler-Fox M, O'Shaughnessy J, Cowan K, Carter C, Doren S, et al. Gene transfer into hematopoietic cells. Implications for cancer therapy. Ann N Y Acad Sci. 1994 May 31; 716:216-24; discussion 224-7.
Score: 0.059
-
Spitzer TR, Areman EM, Cirenza E, Yu M, Dickerson S, Kotula PL, Sacher RA, Cottler-Fox M. The impact of harvest center on quality of marrows collected from unrelated donors. J Hematother. 1994; 3(1):65-70.
Score: 0.057
-
Dunbar CE, Nienhuis AW, Stewart FM, Quesenberry P, O'Shaughnessy J, Cowan K, Cottler-Fox M, Leitman S, Goodman S, Sorrentino BP, et al. Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer. Hum Gene Ther. 1993 Apr; 4(2):205-22.
Score: 0.054
-
Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant. 2002 Dec; 30(12):873-8.
Score: 0.053
-
Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol. 1992 Nov; 10(11):1712-22.
Score: 0.052
-
Pickle LW, Cottler-Fox M. Statistical methods for the analysis of repeated measurements of serum immunoglobulin levels. Semin Hematol. 1992 Jul; 29(3 Suppl 2):116-22.
Score: 0.051
-
Spitzer TR, Cottler-Fox M, Sullivan P, Lynch M, Tefft MC, Pickle LW, Cirenza E, Cahill R, Deeg HJ, Sacher R. Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation. Semin Hematol. 1992 Jul; 29(3 Suppl 2):123-6.
Score: 0.051
-
Cottler-Fox M, Himoe E, Blancato JK, Deeg HJ. Documentation of allogeneic marrow engraftment by DNA analysis of urinary leucocytes. Br J Haematol. 1991 Sep; 79(1):122-3.
Score: 0.048
-
Cottler-Fox M, Lynch M, Pickle LW, Cahill R, Spitzer TR, Deeg HJ. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant. 1991 Jul; 8(1):27-33.
Score: 0.048
-
Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991 Mar; 7(3):193-8.
Score: 0.047
-
Spitzer TR, Himoe E, Cottler-Fox M, Cahill R, Deeg HJ. Long-term stable mixed chimaerism following allogeneic marrow transplantation for severe aplastic anaemia. Br J Haematol. 1990 Sep; 76(1):146-7.
Score: 0.045
-
Greenspan A, Deeg HJ, Cottler-Fox M, Sirdofski M, Spitzer TR, Kattah J. Incapacitating peripheral neuropathy as a manifestation of chronic graft-versus-host disease. Bone Marrow Transplant. 1990 May; 5(5):349-52.
Score: 0.044
-
Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant. 1989 Sep; 4(5):559-65.
Score: 0.042
-
Cottler-Fox M, Lynch M, Deeg HJ, Koss LG. Human polyomavirus: lack of relationship of viruria to prolonged or severe hemorrhagic cystitis after bone marrow transplant. Bone Marrow Transplant. 1989 May; 4(3):279-82.
Score: 0.041
-
Raschko JW, Cottler-Fox M, Abbondanzo SL, Torrisi JR, Spitzer TR, Deeg HJ. Pulmonary fibrosis after bone marrow transplantation responsive to treatment with prednisone and cyclosporine. Bone Marrow Transplant. 1989 Mar; 4(2):201-5.
Score: 0.041
-
Cipolone KM, Carter CS, Yu M, Cottler-Fox M. A semi-automated process for antibody sensitization and washing of mononuclear cells prior to CD34+ cell selection. Prog Clin Biol Res. 1994; 389:667-73.
Score: 0.014
-
Yu M, Cottler-Fox M. Quality assurance in flow cytometry: comparison of three analytical methods for quantifying CD34+ cells in marrow. Prog Clin Biol Res. 1994; 389:729-36.
Score: 0.014
-
Cottler-Fox M, Read EJ, Yu M, Carter C, Klein HG. Mononuclear and CD34+ stem cell recovery after automated Ficoll processing of marrow or peripheral blood stem cells for transplantation. Prog Clin Biol Res. 1992; 377:569-73.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|